Platelet Reactivity Clinical Trial
Official title:
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting. However, a significant proportion of patients is considered clopidogrel resistant and this resistance is shown to be accompanied by future adverse events. The aim of the study is to define in consecutive patients with acute coronary syndrome (ACS) undergoing PCI, those aged>75years and/or weighted<60 Kg with high on-clopidogrel platelet reactivity (Platelet Reactivity Units-PRU≥235) as estimated 24 hours post PCI with the VerifyNow assay. Those patients will be randomized after informed concent in 1:1 fashion to prasugrel 5 mg or clopidogrel 150mg daily. Platelet reactivity will be assessed at day 15 and then treatment crossover will be performed. At day 30 platelet reactivity will be determined as well.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02808039 -
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
|
N/A | |
Completed |
NCT01961856 -
Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
|
Phase 3 | |
Recruiting |
NCT03525145 -
Platelet Reactivity And Clinical ThrombotIC Events Study
|
||
Completed |
NCT01463163 -
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
Recruiting |
NCT03614832 -
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
|
Phase 4 | |
Completed |
NCT01835353 -
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
Completed |
NCT04001894 -
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
|
Phase 4 | |
Recruiting |
NCT05773989 -
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
|
Phase 4 | |
Completed |
NCT01511471 -
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
|
Phase 3 | |
Completed |
NCT00827346 -
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
|
Phase 2/Phase 3 | |
Completed |
NCT00976196 -
Platelet Hyperreactivity Project
|
N/A | |
Recruiting |
NCT05367336 -
Platelet Reactivity With Fentanyl, Morphine, or no Narcotic
|
Early Phase 1 | |
Completed |
NCT03679091 -
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
|
Phase 4 | |
Recruiting |
NCT05657041 -
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
|
Phase 2/Phase 3 |